Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px
Document › Details

AstraZeneca plc. (8/17/17). "Press Release: Lynparza Receives Additional and Broad Approval in the US for Ovarian Cancer".

Region Region United States (USA)
Organisations Organisation AstraZeneca plc (LSE: AZN)
  Group AstraZeneca (Group)
  Organisation 2 FDA (US Food and Drug Administration)
  Group United States (govt)
Products Product Lynparza®
  Product 2 chemotherapeutic
Index term Index term AstraZeneca–Merck (US): cancer drugs, 201707– strategic oncology collab maximising combis of PARP + MEK inhibitors with PD-L1/PD1 medicines
Persons Person Bohen, Sean (AstraZeneca 201509– EVP Global Medicines Developent + CMO before Genentech + Stanford Univ)
  Person 2 Perlmutter, Roger M. (Merck (US) 2013– EVP + President of Merck Research Labs before Amgen 2001–2012)

Record changed: 2017-08-24


Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

More documents for AstraZeneca (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top